Be Cool Pharmaceutics is a small molecule drug development company, focused on creating therapeutics to modulate metabolism and body temperature by mimicking hibernation. BeCool’s lead technology (BCP-190) is a first in class thermolytic; an agent designed to transfer temperature control from the patient to the clinician after cardiac arrest. The mechanism mimics entry into hibernation informed by basic research in CNS control of hibernation in the inventor’s laboratory. The company seeks investors and partners to complete IND enabling studies to support IND submission and first in human studies. The company is located adjacent to the University of Alaska Fairbanks (UAF), Institute of Arctic Biology with a 60- year legacy of hibernation research. Dr. Drew, a world expert in hibernation, leads an NIH-funded Center of Excellence in Hibernation Science at UAF. The Center focuses on discovery and translation of druggable targets in hibernation.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):